Will This Change How You Manage Glaucoma?...
Intraocular pressure (IOP) is usually our primary concern in managing glaucoma - assuming we also understand and always consider additional pathophysiologic dynamics in glaucomatous optic neuropathy. For example, factors involved in glaucomatous progression despite "target IOP" and/or with Normal Tension Glaucoma (NTG). However, also knowing IOP is our #1 modifiable risk factor which continuously fluctuates, it only makes sense our brief in-office measurements every few months are likely not enough. Perhaps hidden IOP spikes are progressing our patients despite "good IOP" in the office.
Findings from the EYEMATE-IO trial may just lead us towards a transformative potential in terms of "perpetual" IOP management. It is being shown this implantable sensor significantly enhances detection accuracy and its findings are associated with early signs of structural glaucomatous progression. This of course is a huge advantage over our "occasional" and very brief in-office methods. By enabling 24/7/365 IOP measurements, this technology gives us invaluable high-yield information. The long-term advantage being a strong correlation between "self-measured" IOP and rates of retinal nerve fiber layer (RNFL) thinning, superior to our usual management.
For us, this advancement represents a paradigm shift towards more personalized effective care and emphasizes the need for continuous management. Refining treatment plans based on individual IOP patterns matters and will lead to more timely intervention - ultimately saving vision.
Go to the article in the American Journal of Ophthalmology HERE.
-JRM
"MODERN GLAUCOMA" on AMAZON
An Amazon #1 Now Available in AUDIOBOOK Format.
READ or LISTEN on Amazon HERE.
OD's...DO YOU KNOW HOW TO BEHAVE?
"5 BEHAVIORS SACRIFICING YOUR MEDICAL AUTHORITY...AND HOW TO FIX".
ATTRACT & RETAIN PATIENTS FOREVER.
PDF (Free) INSTANT DOWNLOAD: HERE.
Responses